electroCore (ECOR) Set to Announce Earnings on Wednesday

electroCore (NASDAQ:ECOR) is scheduled to post its quarterly earnings results after the market closes on Wednesday, August 7th. Analysts expect electroCore to post earnings of ($0.39) per share for the quarter.

electroCore (NASDAQ:ECOR) last announced its earnings results on Wednesday, May 8th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.03). The company had revenue of $5.44 million for the quarter, compared to the consensus estimate of $5.18 million. electroCore had a negative net margin of 88.12% and a negative return on equity of 219.33%. On average, analysts expect electroCore to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

electroCore Trading Down 0.8 %

Shares of NASDAQ ECOR opened at $6.07 on Thursday. The stock has a market capitalization of $39.17 million, a PE ratio of -2.13 and a beta of 0.55. The stock’s fifty day simple moving average is $6.33 and its two-hundred day simple moving average is $6.52. electroCore has a 12-month low of $3.92 and a 12-month high of $8.08.

Insider Activity

In other electroCore news, CEO Daniel S. Goldberger acquired 38,505 shares of the firm’s stock in a transaction dated Wednesday, June 5th. The stock was purchased at an average price of $6.43 per share, for a total transaction of $247,587.15. Following the acquisition, the chief executive officer now owns 249,565 shares in the company, valued at approximately $1,604,702.95. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Company insiders own 13.14% of the company’s stock.

electroCore Company Profile

electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.